OnKure Therapeutics (OKUR) Competitors $2.31 -0.06 (-2.53%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.37 +0.06 (+2.38%) As of 07/25/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OKUR vs. NKTX, FATE, MCRB, GNLX, FTLF, TARA, KRRO, SKYE, ACTU, and ALTSShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Nkarta (NKTX), Fate Therapeutics (FATE), Seres Therapeutics (MCRB), Genelux (GNLX), FitLife Brands (FTLF), Protara Therapeutics (TARA), Korro Bio (KRRO), Skye Bioscience (SKYE), Actuate Therapeutics (ACTU), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry. OnKure Therapeutics vs. Its Competitors Nkarta Fate Therapeutics Seres Therapeutics Genelux FitLife Brands Protara Therapeutics Korro Bio Skye Bioscience Actuate Therapeutics ALT5 Sigma Nkarta (NASDAQ:NKTX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk. Which has more volatility & risk, NKTX or OKUR? Nkarta has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Is NKTX or OKUR more profitable? Nkarta's return on equity of -26.64% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NkartaN/A -26.64% -21.62% OnKure Therapeutics N/A -49.13%-45.72% Do analysts rate NKTX or OKUR? Nkarta currently has a consensus price target of $14.33, suggesting a potential upside of 563.58%. OnKure Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 1,299.71%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Nkarta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Which has higher earnings & valuation, NKTX or OKUR? Nkarta is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNkartaN/AN/A-$108.79M-$1.51-1.43OnKure TherapeuticsN/AN/A-$52.67M-$5.26-0.44 Do institutionals and insiders hold more shares of NKTX or OKUR? 80.5% of Nkarta shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 8.4% of Nkarta shares are owned by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor NKTX or OKUR? In the previous week, Nkarta had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for Nkarta and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Nkarta's score of 0.86 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Nkarta Positive OnKure Therapeutics Very Positive SummaryNkarta beats OnKure Therapeutics on 7 of the 13 factors compared between the two stocks. Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.02M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-0.4421.1828.1020.05Price / SalesN/A286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book0.308.378.665.87Net Income-$52.67M-$55.19M$3.25B$258.55M7 Day Performance-0.86%5.88%4.22%3.73%1 Month Performance-8.33%17.33%10.51%11.75%1 Year PerformanceN/A4.42%34.40%18.03% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics3.4005 of 5 stars$2.31-2.5%$32.33+1,299.7%N/A$32.02MN/A-0.44N/APositive NewsNKTXNkarta1.768 of 5 stars$1.89+3.3%$14.33+658.4%-68.7%$134.11MN/A-1.25140Positive NewsFATEFate Therapeutics3.6909 of 5 stars$1.14-0.9%$3.83+236.3%-77.0%$130.64M$13.63M-0.77550MCRBSeres Therapeutics3.5129 of 5 stars$14.85+18.1%$73.67+396.1%-46.6%$129.64M$126.32M-3.23330Positive NewsHigh Trading VolumeGNLXGenelux1.2346 of 5 stars$3.38-1.5%$17.75+425.1%+74.0%$127.54MN/A-3.8410Analyst ForecastGap UpFTLFFitLife Brands4.0839 of 5 stars$13.09+0.5%$20.50+56.6%-23.6%$122.92M$64.47M15.5820News CoveragePositive NewsGap DownTARAProtara Therapeutics2.1594 of 5 stars$3.16+3.6%$20.50+548.7%+45.4%$121.91MN/A-1.8430KRROKorro Bio1.7879 of 5 stars$12.97+2.0%$102.43+689.7%-69.4%$121.79M$2.27M-1.3770News CoverageAnalyst ForecastSKYESkye Bioscience2.5361 of 5 stars$3.93-1.3%$16.60+322.4%-33.7%$121.73MN/A-4.7911News CoverageGap UpACTUActuate Therapeutics2.252 of 5 stars$6.20+1.0%$20.50+230.6%N/A$121.64MN/A0.0010News CoverageALTSALT5 Sigma0.1039 of 5 stars$6.96-11.7%N/A+254.0%$121.45M$12.53M0.00170 Related Companies and Tools Related Companies Nkarta Alternatives Fate Therapeutics Alternatives Seres Therapeutics Alternatives Genelux Alternatives FitLife Brands Alternatives Protara Therapeutics Alternatives Korro Bio Alternatives Skye Bioscience Alternatives Actuate Therapeutics Alternatives ALT5 Sigma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKUR) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
